USD 4.835
↓ -0.005 (-0.1%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| HUMA | -0.1 | -6.7 | -15.2 | -21.3 | -25.3 | 93.4 | -54.7 | -50 | -50 | -50 |
| S&P 500 | -1.3 | -1.8 | 1.0 | 5.9 | 10.6 | 30.4 | 25.4 | 88.1 | 187.6 | 33142.5 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | HUMA |
| name | Humacyte, Inc. |
| price | 4.835 |
| changes percentage | -0.1033 |
| change | -0.005 |
| day low | 4.81 |
| day high | 5.02 |
| year high | 9.97 |
| year low | 2.43 |
| market cap | 608533100 |
| price avg 50 | 5.4289 |
| price avg 200 | 5.3722 |
| exchange | NASDAQ |
| volume | 3051170 |
| avg volume | 2908639 |
| open | 4.91 |
| previous close | 4.84 |
| eps | -1.15 |
| pe | -4.2 |
| earnings announcement | 2025-03-20T12:00:00.000+0000 |
| shares outstanding | 125860000 |
| timestamp | 2024-11-15 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001818382 | |||
| revenue | 0 | 1565000 | -100.00 |
| gross profit | -76550000 | -6690000 | -1044.25 |
| gross profit ratio | 0 | -4.27 | 100.00 |
| research and development expenses | 76550000 | 63260000 | 21.01 |
| operating expenses | 23497000 | 84578000 | -72.22 |
| interest income | 5467000 | 2629000 | 107.95 |
| interest expense | -6599000 | 6200000 | -206.44 |
| ebitda | -96458000 | 2490000 | -3973.82 |
| ebitdaratio | 0 | -102.46 | 100.00 |
| operating income | -100047000 | -84578000 | -18.29 |
| operating income ratio | 0 | -54.04 | 100.00 |
| net income | -110776000 | 64219000 | -272.50 |
| net income ratio | 0 | 41.03 | -100.00 |
| eps | -1.07 | 0.62 | -272.58 |
Revenue Growth: revenue decreased to 0 million in 2023 from 2 million in 2022 representing a change of -100.0%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to -77 million in 2023 from -7 million in 2022 representing a change of -1044.25%. This indicates a sales profitability decline, which is a negative sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -96 million in 2023 from 2 million in 2022 representing a change of -3973.82%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -100 million in 2023 from -85 million in 2022 representing a change of -18.29%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -111 million in 2023 from 64 million in 2022 representing a change of -272.5%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -1.07 in 2023 from -1.07 in 2022 representing a change of -272.58%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses increased to 77 million in 2023 from 63 million in 2022 representing a change of 21.01%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 23 million in 2023 from 85 million in 2022 representing a change of -72.22%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001818382 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | -1823000 | 100.00 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 22926000 | 23753000 | -3.48 |
| operating expenses | 30233000 | 27676000 | 9.24 |
| interest income | 911000 | 1310000 | -30.46 |
| interest expense | -2438000 | 2515000 | -196.94 |
| ebitda | -30233000 | -52325000 | 42.22 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -30233000 | -29499000 | -2.49 |
| operating income ratio | 0 | 0 | NaN |
| net income | 0 | -56663000 | 100.00 |
| net income ratio | 0 | 0 | NaN |
| eps | 0 | -0.48 | 100.00 |
Gross Profit: Gross Profit increased to 0 million in 2024Q3 from -2 million in 2024Q2 representing a change of 100.0%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Income: Operating income increased to -30 million in 2024Q3 from -29 million in 2024Q2 representing a change of -2.49%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to 0 million in 2024Q3 from -57 million in 2024Q2 representing a change of 100.0%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 0 in 2024Q3 from 0 in 2024Q2 representing a change of 100.0%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 23 million in 2024Q3 from 24 million in 2024Q2 representing a change of -3.48%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 30 million in 2024Q3 from 28 million in 2024Q2 representing a change of 9.24%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -30 million in 2024Q3 from -52 million in 2024Q2 representing a change of 42.22%. The decrease in EBITDA indicates declined operational efficiency and profitability.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001818382 | |||
| total assets | 128223000 | 204302000 | -37.24 |
| total liabilities | 114677000 | 87374000 | 31.25 |
| total equity | 13546000 | 116928000 | -88.42 |
| cash and cash equivalents | 80448000 | 149772000 | -46.29 |
| short term investments | 0 | 2107000 | -100.00 |
| long term investments | 0 | 0 | NaN |
| total current assets | 83278000 | 154208000 | -46.00 |
| total non current assets | 44945000 | 50094000 | -10.28 |
| total current liabilities | 18443000 | 19580000 | -5.81 |
| total non current liabilities | 96234000 | 67794000 | 41.95 |
| common stock | 10000 | 543466000 | -100.00 |
| retained earnings | -537314000 | -426538000 | -25.97 |
| total debt | 58106000 | 47760000 | 21.66 |
Total Assets: Total Assets decreased to 128 million in 2023 from 204 million in 2022 representing a change of -37.24%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 115 million in 2023 from 87 million in 2022 representing a change of 31.25%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 14 million in 2023 from 117 million in 2022 representing a change of -88.42%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 80 million in 2023 from 150 million in 2022 representing a change of -46.29%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 0 million in 2023 from 2 million in 2022 representing a change of -100.0%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 83 million in 2023 from 154 million in 2022 representing a change of -46.0%. This indicates a worsen liquidity position.
Common Stock: Common Stock decreased to 0 in 2023 from 543 in 2022 representing a change of -100.0%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -537 million in 2023 from -427 million in 2022 representing a change of -25.97%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 58 million in 2023 from 48 million in 2022 representing a change of 21.66%. This indicates an increase in overall debt burden.
Total Current Liabilities: Total Current Liabilities decreased to 18 million in 2023 from 20 million in 2022 representing a change of -5.81%. This indicates a lower short-term debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001818382 | |||
| total assets | 114764000 | 138281000 | -17.01 |
| total liabilities | 178485000 | 166568000 | 7.15 |
| total equity | -63721000 | -28287000 | -125.27 |
| cash and cash equivalents | 20571000 | 93563000 | -78.01 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 209000 | -100.00 |
| total current assets | 23005000 | 96110000 | -76.06 |
| total non current assets | 91759000 | 42171000 | 117.59 |
| total current liabilities | 20942000 | 17757000 | 17.94 |
| total non current liabilities | 157543000 | 148811000 | 5.87 |
| common stock | 12000 | 12000 | 0.00 |
| retained earnings | -665075000 | -625873000 | -6.26 |
| total debt | 17267000 | 17925000 | -3.67 |
Total Assets: Total Assets decreased to 115 million in 2024Q3 from 138 million in 2024Q2 representing a change of -17.01%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 178 million in 2024Q3 from 167 million in 2024Q2 representing a change of 7.15%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to -64 million in 2024Q3 from -28 million in 2024Q2 representing a change of -125.27%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 21 million in 2024Q3 from 94 million in 2024Q2 representing a change of -78.01%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 23 million in 2024Q3 from 96 million in 2024Q2 representing a change of -76.06%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 21 million in 2024Q3 from 18 million in 2024Q2 representing a change of 17.94%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -665 million in 2024Q3 from -626 million in 2024Q2 representing a change of -6.26%. This indicates an accumulated losses.
Total Debt: Total Debt decreased to 17 million in 2024Q3 from 18 million in 2024Q2 representing a change of -3.67%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001818382 | |||
| net change in cash | -68971000 | -67730000 | -1.83 |
| operating cash flow | -73305000 | -71129000 | -3.06 |
| free cash flow | -75585000 | -72177000 | -4.72 |
| capital expenditure | -2280000 | -1048000 | -117.56 |
| depreciation and amortization | 7719000 | 8210000 | -5.98 |
| deferred income tax | 0 | -173000 | 100.00 |
| stock based compensation | 6828000 | 6184000 | 10.41 |
| accounts payables | 4811000 | -509000 | 1045.19 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | -5893000 | 100.00 |
| investments in property plant and equipment | -2280000 | -1048000 | -117.56 |
| net cash used for investing activites | -173000 | 4845000 | -103.57 |
| debt repayment | -34066000 | -1981000 | -1619.64 |
| common stock issued | 566000 | 535000 | 5.79 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 4507000 | -1446000 | 411.69 |
| cash at end of period | 80801000 | 149772000 | -46.05 |
| accounts receivables | 31000 | 145000 | -78.62 |
| cash at beginning of period | 149772000 | 217502000 | -31.14 |
Net Change in Cash: Net Change in Cash decreased to -69 million in 2023 from -68 million in 2022 representing a change of -1.83%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -73 million in 2023 from -71 million in 2022 representing a change of -3.06%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -76 million in 2023 from -72 million in 2022 representing a change of -4.72%. This indicates a decrease in cash generated after accounting for capital expenditures.
Deferred Income Tax: Deferred Income Tax increased to 0 million in 2023 from 0 million in 2022 representing a change of 100.0%. This indicates that the company's tax liability for future periods has increased.
Stock-Based Compensation: Stock-Based Compensation increased to 7 million in 2023 from 6 million in 2022 representing a change of 10.41%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 5 million in 2023 from 1 million in 2022 representing a change of 1045.19%. This indicates that the company has increased its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure decreased to -2 million in 2023 from -1 million in 2022 representing a change of -117.56%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Receivables: Accounts Receivables decreased to 0 million in 2023 from 0 million in 2022 representing a change of -78.62%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001818382 | |||
| operating cash flow | -71316788.82 | -21291000 | -234.96 |
| free cash flow | -72825788.82 | -21475000 | -239.12 |
| capital expenditure | -1509000 | -184000 | -720.11 |
| depreciation and amortization | 3819000 | 1823000 | 109.49 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 4443000 | 1437000 | 209.19 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | 497087 | 2311000 | -78.49 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -1509000 | -184000 | -720.11 |
| net cash used for investing activites | -1509000 | -184000 | -720.11 |
| debt repayment | 0 | -404000 | 100.00 |
| common stock issued | 43396000 | 787000 | 5414.10 |
| common stock repurchased | 708000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 63272369 | -467000 | 13648.69 |
| net change in cash | 70923616 | -21942000 | 423.23 |
| cash at end of period | 70924000 | 93563000 | -24.20 |
| cash at beginning of period | 383.4 | 115505000 | -100.00 |
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0 | 0.02 | -100.00 |
| net income per share | -1.07 | 0.62 | -271.88 |
| operating cash flow per share | -0.71 | -0.69 | -2.69 |
| free cash flow per share | -0.73 | -0.7 | -4.35 |
| cash per share | 0.78 | 1.47 | -47.22 |
| book value per share | 0.13 | 1.13 | -88.46 |
| tangible book value per share | 0.13 | 1.13 | -88.46 |
| shareholders equity per share | 0.13 | 1.13 | -88.46 |
| interest debt per share | 0.33 | 0.34 | -1.76 |
| market cap | 293713475.92 | 217438382.26 | 35.08 |
| enterprise value | 271371475.92 | 115426382.26 | 135.10 |
| pe ratio | -2.65 | 3.39 | -178.31 |
| price to sales ratio | 0 | 138.94 | -100.00 |
| pocfratio | -4.01 | -3.06 | -31.07 |
| pfcf ratio | -3.89 | -3.01 | -28.99 |
| pb ratio | 21.68 | 1.86 | 1065.99 |
| ptb ratio | 21.68 | 1.86 | 1065.99 |
| ev to sales | 0 | 73.75 | -100.00 |
| enterprise value over ebitda | -2.81 | 46.36 | -106.07 |
| ev to operating cash flow | -3.7 | -1.62 | -128.12 |
| ev to free cash flow | -3.59 | -1.6 | -124.50 |
| earnings yield | -0.38 | 0.3 | -227.70 |
| free cash flow yield | -0.26 | -0.33 | 22.47 |
| debt to equity | 3.04 | 0.25 | 1130.66 |
| debt to assets | 0.32 | 0.14 | 127.16 |
| net debt to ebitda | 0.23 | -40.97 | 100.57 |
| current ratio | 4.52 | 7.88 | -42.67 |
| interest coverage | 15.16 | -13.64 | 211.14 |
| income quality | 0.66 | 5.94 | -88.87 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 14.62 | -100.00 |
| research and ddevelopement to revenue | 0 | 40.42 | -100.00 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.03 | -0.01 | -111.10 |
| capex to revenue | 0 | 0.67 | -100.00 |
| capex to depreciation | 0.3 | 0.13 | 131.40 |
| stock based compensation to revenue | 0 | 3.95 | -100.00 |
| graham number | 1.78 | 3.99 | -55.46 |
| roic | -1.83 | 3.11 | -158.70 |
| return on tangible assets | -0.86 | 0.31 | -374.85 |
| graham net net | -0.33 | 0.63 | -152.87 |
| working capital | 64835000 | 134628000 | -51.84 |
| tangible asset value | 13546000 | 116928000 | -88.42 |
| net current asset value | -31399000 | 66834000 | -146.98 |
| invested capital | 109780000 | 184722000 | -40.57 |
| average receivables | 15500 | 103500 | -85.02 |
| average payables | 4042500 | 1844500 | 119.17 |
| average inventory | -15500 | -15499.5 | -0.00 |
| days sales outstanding | 0 | 7.23 | -100.00 |
| days payables outstanding | 30.95 | 70.52 | -56.12 |
| days of inventory on hand | 0 | -1.37 | 100.00 |
| receivables turnover | 0 | 50.48 | -100.00 |
| payables turnover | 11.8 | 5.18 | 127.90 |
| inventory turnover | 0 | -266.29 | 100.00 |
| roe | -8.18 | 0.55 | -1588.98 |
| capex per share | 0.02 | 0.01 | 116.78 |
ROE: Return on Equity (ROE) decreased to -8.18 on 2023-12-31 from 0.55 on 2022-12-31, representing a change of -1588.98%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -2.65 on 2023-12-31 from 3.39 on 2022-12-31, representing a change of -178.31%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 4.52 on 2023-12-31 from 7.88 on 2022-12-31, representing a change of -42.67%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 3.04 on 2023-12-31 from 0.25 on 2022-12-31, representing a change of 1130.66%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. A ratio of 2.0 or higher is usually considered risky.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| HUMA | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | 0 | -0.48 | 100.00 |
| operating cash flow per share | -0.6 | -0.18 | -234.31 |
| free cash flow per share | -0.61 | -0.18 | -238.45 |
| cash per share | 0.17 | 0.79 | -78.06 |
| book value per share | -0.53 | -0.24 | -124.82 |
| tangible book value per share | -0.53 | -0.24 | -124.82 |
| shareholders equity per share | -0.53 | -0.24 | -124.82 |
| interest debt per share | 0.12 | 0.04 | 178.35 |
| market cap | 649582593.6 | 639968036.97 | 1.50 |
| enterprise value | 646278593.6 | 564330036.97 | 14.52 |
| pe ratio | 0 | -2.82 | 100.00 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -9.11 | -30.06 | 69.70 |
| pfcf ratio | -8.92 | -29.8 | 70.07 |
| pb ratio | -10.19 | -22.62 | 54.94 |
| ptb ratio | -10.19 | -22.62 | 54.94 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -21.38 | -10.79 | -98.20 |
| ev to operating cash flow | -9.06 | -26.51 | 65.81 |
| ev to free cash flow | -8.87 | -26.28 | 66.23 |
| earnings yield | 0 | -0.09 | 100.00 |
| free cash flow yield | -0.11 | -0.03 | -234.10 |
| debt to equity | -0.27 | -0.1 | -173.56 |
| debt to assets | 0.15 | 0.02 | 642.52 |
| net debt to ebitda | 0.11 | 1.45 | -92.44 |
| current ratio | 1.1 | 5.41 | -79.70 |
| interest coverage | 12.4 | -11.73 | 205.73 |
| income quality | 0.56 | 0.38 | 48.50 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.02 | -0.01 | -144.84 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0.4 | 0.1 | 291.48 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 0 | 1.59 | -100.00 |
| roic | None | 1.16 | NaN |
| return on tangible assets | 0 | -0.41 | 100.00 |
| graham net net | -1.32 | -0.61 | -115.88 |
| working capital | 2063000 | 78353000 | -97.37 |
| tangible asset value | -63721000 | -28287000 | -125.27 |
| net current asset value | -155480000 | -70458000 | -120.67 |
| invested capital | 42326000 | 119709000 | -64.64 |
| average receivables | 0 | 0 | NaN |
| average payables | 6454000 | 4728500 | 36.49 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 296.46 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0.3 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | 0 | 2.0 | -100.00 |
| capex per share | 0.01 | 0.0 | 718.50 |
ROE: Return on Equity (ROE) decreased to 0.00 on 2024-09-30 Q3 from 2.00 on 2024-06-30 Q2, representing a change of -100.00%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 0.00 on 2024-09-30 Q3 from -2.82 on 2024-06-30 Q2, representing a change of 100.00%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to -0.27 on 2024-09-30 Q3 from -0.10 on 2024-06-30 Q2, representing a change of -173.56%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Current Ratio: Current Ratio decreased to 1.10 on 2024-09-30 Q3 from 5.41 on 2024-06-30 Q2, representing a change of -79.70%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Negative Sentiment: Discounted Cash Flow value is 0.22 which is lower than current price 4.83, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Neutral
Publish Date: 2024-11-15 13:32:00
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA), a biotechnology company focused on developing acellular tissue engineered vessels, has faced significant setbacks in recent months due to regulatory scrutiny from the U.S. Food and Drug Administration (FDA). The company's stock price has plummeted following disclosures of FDA violations at its manufacturing facility and delays in the approval process for its flagship product.
Sentiment: Positive
Publish Date: 2024-11-15 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA). Investors who purchased Humacyte securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUMA.
Sentiment: Positive
Publish Date: 2024-11-14 17:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ:HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-14 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA). Investors who purchased Humacyte securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUMA.
Sentiment: Positive
Publish Date: 2024-11-13 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA). Investors who purchased Humacyte securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUMA.
Sentiment: Positive
Publish Date: 2024-11-12 21:00:00
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) on behalf of Humacyte stockholders. Our investigation concerns whether Humacyte has violated the federal securities laws and/or engaged in other unlawful business practices.
Sentiment: Positive
Publish Date: 2024-11-12 16:30:00
NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ:HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-12 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA). Investors who purchased Humacyte securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUMA.
Sentiment: Negative
Publish Date: 2024-11-11 16:37:00
SAN FRANCISCO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- On October 17, 2024, the U.S. Federal Food & Drug Administration (“FDA”) published its April 5, 2024 report addressed to Humacyte's Chief Operating Officer (Heather Prichard) detailing problems with Humacyte's facilities. The FDA's April 5, 2024 report submitted to Prichard appears to potentially contradict her assurances to investors at an earnings call on May 12, 2024 in response to analyst questions.
Sentiment: Positive
Publish Date: 2024-11-11 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA). Investors who purchased Humacyte securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUMA.
Sentiment: Negative
Publish Date: 2024-11-11 07:25:00
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Humacyte, Inc. ("Humacyte, Inc.") (NASDAQ:HUMA) concerning possible violations of federal securities laws. On October 17, 2024, the FDA revealed that it had identified several violations at Humacyte's North Carolina facility, including "no microbial quality assurance" and "no microbial testing," and "that quality oversight is inadequate.
Sentiment: Positive
Publish Date: 2024-11-10 12:00:00
NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-10 12:00:00
NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-10 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA). Investors who purchased Humacyte securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUMA.
Sentiment: Positive
Publish Date: 2024-11-09 20:12:48
Humacyte, Inc. (NASDAQ:HUMA ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Lauren Marek - LifeSci Advisors Laura Niklason - President and CEO Dale Sander - CFO and Chief Corporate Development Officer Conference Call Participants Ryan Zimmerman - BTIG Josh Jennings - TD Cowen & Company Kristen Kluska - Cantor Fitzgerald Bruce Jackson - Benchmark Company Vernon Bernardino - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the Humacyte Third Quarter 2024 Results Conference Call.
Sentiment: Positive
Publish Date: 2024-11-08 12:00:00
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ:HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sentiment: Positive
Publish Date: 2024-11-08 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / November 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA). Investors who purchased Humacyte securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUMA.
Sentiment: Neutral
Publish Date: 2024-11-08 09:16:00
SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA), a biotechnology company focused on developing acellular tissue engineered vessels, has faced significant setbacks in recent months due to regulatory scrutiny from the U.S. Food and Drug Administration (FDA). The company's stock price has plummeted following disclosures of FDA violations at its manufacturing facility and delays in the approval process for its flagship product.
Sentiment: Negative
Publish Date: 2024-11-08 08:00:00
- FDA review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma is ongoing -
Sentiment: Negative
Publish Date: 2024-11-08 07:30:00
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Humacyte, Inc. ("Humacyte, Inc.") (NASDAQ:HUMA) concerning possible violations of federal securities laws. On October 17, 2024, the FDA revealed that it had identified several violations at Humacyte's North Carolina facility, including "no microbial quality assurance" and "no microbial testing," and "that quality oversight is inadequate.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
